Tai Mei Chee, Kajino Taisuke, Nakatochi Masahiro, Arima Chinatsu, Shimada Yukako, Suzuki Motoshi, Miyoshi Hiroyuki, Yatabe Yasushi, Yanagisawa Kiyoshi, Takahashi Takashi
Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Subteam for Manipulation of Cell Fate, BioResource Center, RIKEN, Tsukuba, Japan and.
Carcinogenesis. 2015 Dec;36(12):1464-73. doi: 10.1093/carcin/bgv152. Epub 2015 Oct 18.
Accumulating evidence indicates that altered miRNA expression is crucially involved in lung cancer development, though scant information is available regarding how MYC, an archetypical oncogene, is regulated by miRNAs, especially via a mechanism involving MYC cofactors. In this study, we attempted to identify miRNAs involved in regulation of MYC transcriptional activity in lung cancer. To this end, we utilized an integrative approach with combinatorial usage of miRNA and mRNA expression profile datasets of patient tumor tissues, as well as those of MYC-inducible cell lines in vitro. In addition to miRNAs previously reported to be directly regulated by MYC, including let-7 and miR-17-92, our strategy also helped to identify miR-342-3p as capable of indirectly regulating MYC activity via direct repression of E2F1, a MYC-cooperating molecule. Furthermore, miR-342-3p module activity, which we defined as a gene set reflecting the experimentally substantiated influence of miR-342-3p on mRNA expression, was found to be inversely correlated with MYC activity reflected by MYC module activity in three independent datasets of lung adenocarcinoma patients obtained from the Director's Challenge Consortium of the United States (P = 1.94 × 10(-73)), the National Cancer Center of Japan (P = 9.05 × 10(-34)) and the present study (P = 1.17 × 10(-19)). Our integrative approach appears to be useful to elucidate inter-regulatory relationships between miRNAs and protein coding genes of interest, even those present in patient tumor tissues, which remains a challenge to better understand the pathogenesis of this devastating disease.
越来越多的证据表明,微小RNA(miRNA)表达的改变在肺癌发展中起着至关重要的作用,尽管关于典型致癌基因MYC如何受miRNA调控,尤其是通过涉及MYC辅助因子的机制的信息很少。在本研究中,我们试图鉴定参与肺癌中MYC转录活性调控的miRNA。为此,我们采用了一种综合方法,结合使用患者肿瘤组织以及体外MYC诱导细胞系的miRNA和mRNA表达谱数据集。除了先前报道的直接受MYC调控的miRNA,包括let-7和miR-17-92,我们的策略还帮助鉴定出miR-342-3p能够通过直接抑制E2F1(一种MYC协同分子)间接调控MYC活性。此外,我们将miR-342-3p模块活性定义为反映miR-342-3p对mRNA表达的实验证实影响的基因集,发现在从美国主任挑战联盟(P = 1.94×10^(-73))、日本国立癌症中心(P = 9.05×10^(-34))和本研究(P = 1.17×10^(-19))获得的三个独立肺腺癌患者数据集中,miR-342-3p模块活性与由MYC模块活性反映的MYC活性呈负相关。我们的综合方法似乎有助于阐明miRNA与感兴趣的蛋白质编码基因之间的相互调控关系,即使是存在于患者肿瘤组织中的那些,这对于更好地理解这种毁灭性疾病的发病机制仍然是一个挑战。